What does IRNMIBC — research and development expense mean?

This metric represents the total operating costs specifically allocated to the research and development activities for the IRNMIBC clinical program. It captures expenditures related to drug discovery, preclinical studies, and clinical trial execution for this specific therapeutic pipeline asset. Monitoring these costs provides insight into the company's capital allocation strategy and the progress of its precision medicine development efforts.

Tyra Biosciences, Inc. TYRA IRNMIBC — Research And Development Expense

Other segment segments

Personnel Costs

$11.79M+46.9%

ACH

$4.31M+20.1%

FGFR Discovery

$2.53M-19.2%

LGUTUC

$2.44M—

Facilities And Other Costs

$1.63M+16.3%

MUC

$1.61M-50.4%

Other Development Programs

$849K+65.2%

Similar metrics at other companies

NRIXInternal research and development expenses — R&D

$57.07M+12.2%

IRONInternal Research And Development — Research And Development Expense

$11.31M+67.6%

INVAInternal Expenses — Research And Development Expense

$2.64M+95.9%

RAPPOther Costs — Research And Development Expense

$1.97M+24.7%

MLYSResearch and development expenses

$4.59M-52.5%

ANABImsidolimab — Research And Development Expense Reversal Excluding Acquired In Process Cost

$21K+111%

Other financials

Income statement

See full

Operating income-$42.0M-31.9%

Net income-$39.3M-39.6%

EPS (diluted)-$0.64-36.2%

Balance sheet

See full

Cash & equivalents$85.0M-15.7%

Total debt$5.7M-6.9%

Total equity$387.6M+19.8%

Total assets$412.0M+20.0%

Cash flow

See full

Operating cash flow-$32.6M-27.9%

CapEx$88.0K+529%

Free cash flow-$32.7M-28.2%

Valuation

See full

Market cap$1.79B+318%

Enterprise value$1.71B+397%

Returns & leverage

See full

Return on equity-36.9%+21.1pp

Debt / equity0×0.0×

Current ratio20.5×-2.3×

Where this comes from

Reported directly by Tyra Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tyra Biosciences, Inc.'s irnmibc — research and development expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Tyra Biosciences, Inc.'s IRNMIBC — research and development expense?: Tyra Biosciences, Inc. (TYRA) reported IRNMIBC — research and development expense of $5.25M in Q1 2026.
What does IRNMIBC — research and development expense mean?: This metric represents the total operating costs specifically allocated to the research and development activities for the IRNMIBC clinical program. It captures expenditures related to drug discovery, preclinical studies, and clinical trial execution for this specific therapeutic pipeline asset. Monitoring these costs provides insight into the company's capital allocation strategy and the progress of its precision medicine development efforts.